Generalizability of VICTORION-1 PREVENT enrollment criteria to the United States population
Many primary prevention patients have high CV risk, significant comorbidity burden, and are eligible for lipid-lowering therapy, yet rates of treatment are low. Public health interventions to improve CV risk factor management are necessary.
Authors
- Deepak L. Bhatt (ORCID: https://orcid.org/0000-0002-1278-6245)
- Manesh R. Patel (ORCID: https://orcid.org/0000-0002-2393-0855)
- Catrin Deck
- Anastasia Lesogor
- Rahul Aggarwal (ORCID: https://orcid.org/0000-0002-4746-8511)
- Pam R. Taub (ORCID: https://orcid.org/0000-0002-0684-0655)
- Erik S.G. Stroes (ORCID: https://orcid.org/0000-0001-9555-6260)
- Marc P. Bonaca (ORCID: https://orcid.org/0000-0002-9860-3584)
- Stephan Windecker
Institutions
- Brigham and Women's Hospital (US)
- Novartis (Switzerland) (CH)
- Harvard University (US)
- University Hospital of Bern (CH)
- University of California San Diego (US)
- Clinical Research Institute (US)
- Mount Sinai Hospital (US)
- Amsterdam University Medical Centers (NL)
- Duke University Hospital (US)
- University of Colorado Denver (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- American Journal of Preventive Cardiology
- Published
- 2025-03-08
- DOI
- https://doi.org/10.1016/j.ajpc.2025.100957
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00